Ronald W. Allen, Chairman
Mr. Allen was named to the Company’s Board in September 2008.  Mr. Allen retired as Delta’s Chairman of the Board, President and Chief Executive Officer in July 1997 after having held those positions since 1987.  He is Interim President and Chief Executive Officer of Aaron's, Inc., and is a Director of The Coca-Cola Company,  Aircastle Limited and Forward Air Corporation. He is also a board member of the St. Joseph’s Translational Research Institute, which endeavors to turn new medical discoveries into tangible cures. He serves on the nomination committee.

Ronald W. Hart, Ph.D., Vice Chairman
Dr. Hart has served as a member of Guided Therapeutics’ Board of Directors since March 2007.  He has published over 600 peer-reviewed publications.  In 1980, Dr. Hart was appointed Director of the National Center for Toxicological Research, the research arm of the FDA, a position he held until 1992.  In 1992, Dr. Hart was the first ever Presidential Appointee to the position of Distinguished Scientist in Residence for the U.S. Public Health Service/FDA, a position he held until his retirement in 2000.  Dr. Hart currently serves on the Boards of Directors of Motor Excellence, St. Renatus, SNTech, Inc., AeroFarms, Inc., and GeoTherm, Inc., and has helped in the development of business strategy for a number of start-up companies. He is chairman of the nomination committee.

Mark L. Faupel, Ph.D, President and CEO and acting CFO
Dr. Faupel has more than 25 years of experience as a senior executive developing non-invasive alternatives to surgical biopsies and blood tests, especially in the area of cancer screening and diagnostics. Prior to coming to SpectRx in 1998 as Vice President of Business Development and then co-founding Guided Therapeutics, Dr. Faupel was a senior executive and co-founder of Biofield Corp. In 2007, he became President and CEO of Guided Therapeutics. He is the inventor on 20 U.S. patents and author of numerous scientific publications and presentations, appearing in such peer-reviewed journals as The Lancet, Cancer, The European Journal of Radiology and Diabetes Technology & Therapeutics. He has served as a member of the European School of Oncology Task Force and on National Institutes of Health review panels.  Dr. Faupel earned his Ph.D. in neuroanatomy and physiology from the University of Georgia.

John E. Imhoff, M.D., Southeast Eye Center (Formally Imhoff Eye Center)

Dr. Imhoff has served as a member of our Board of Directors since April 2006.  Dr. Imhoff is an ophthalmic surgeon who specializes in cataract and refractive surgery.  He presently serves as a member of the Hawaiian Eye Foundation’s Scientific Advisory Board.  He is also one of our principal shareholders and invests in many other private and public companies.  He has a B.S. in Industrial Engineering from Oklahoma State University, an M.D. from the University of Oklahoma and completed his ophthalmic residency at the Dean A. McGee Eye Institute. He has worked as an ophthalmic surgeon and owner of Southeast Eye Center since 1983. He serves on the compensation and audit committees.

Michael C. James, Managing Partner, Kuekenhof Capital Management, LLC
Mr. James has served as a member of our board of directors since March 2007. Mr. James is also the Managing Partner of Kuekenhof Capital Management, LLC, a private investment management company. He also holds the position of Managing Director of Kuekenhof Equity Fund, L.P. and Kuekenhof Partners, L.P. Mr. James currently sits on the Board of Directors of Millennium Biotechnologies Group, Inc.  Mr. James was Chief Executive Officer of Nestor, Inc. from January 2009 to September 2009.  He was on the Board of Directors of Nestor, Inc. from July 2006 to June 2009.  He was employed by Moore Capital Management, Inc., a private investment management company from 1995 to 1999 and held position of Partner. He was employed by Buffalo Partners, L.P., a private investment management company from 1991 to 1994 and held the position of Chief Financial and Administrative Officer. He was employed by National Discount Brokers from 1986 to 1991 and held positions of Treasurer and Chief Financial Officer. He began his career in 1980 as a staff accountant with Eisner LLP. Mr. James received a B.S. degree in Accounting from Fairleigh Dickinson University in 1980. He is chairman of the audit and compensation committees.

Jonathan M. Niloff, M.D., MedVentive, Inc.

Dr. Niloff has served as a director since May 2010.  As Chief Medical Officer of MedVentive since 2000, Dr. Niloff is responsible for the overall performance and strategic direction of that company. He is currently an Associate Professor of Obstetrics, Gynecology, and Reproductive Biology at Harvard Medical School. Prior to joining MedVentive, Dr. Niloff served as President of the Beth Israel Deaconess Physicians Organization, Medical Director for Obstetrics and Gynecology for its Affiliated Physicians Group, and Chief of Gynecology at New England Deaconess Hospital. He has deep expertise in all aspects of medical cost and quality improvement, and has published extensively on the topic of gynecologic oncology including the development of the CA125 test for ovarian cancer. Dr. Niloff received his undergraduate education at The Johns Hopkins University, an MD degree from McGill University, and an MBA degree from Boston University. He serves on the audit committee.